On October 6, 2026 Beactica Therapeutics AB, a Swedish precision medicine company, reported the selection of BEA-28 as a preclinical candidate for its TEAD programme, which is aimed at developing novel therapies for a range of aggressive, difficult-to-treat solid tumours, including cancers where resistance to existing treatments remains a major clinical challenge.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BEA-28 is a first-in-class small molecule targeted degrader of the TEAD transcription factors, key effectors of the Hippo-YAP/TAZ pathway. Rather than blocking a binding pocket, BEA-28 removes the TEAD proteins and all their functions – an approach suited to cancers where pathway activity drives tumour growth or treatment resistance. In preclinical studies, BEA-28 showed robust tumour regressions at well-tolerated doses, and restored sensitivity to KRAS inhibitors in resistant models. The programme advances a biomarker-led, combination strategy, with a high unmet need cancer as the lead indication.

"Selecting BEA-28 as a preclinical candidate reflects the strength of our TEAD degrader programme and our confidence in the compound’s differentiated profile. The compound has met all predefined success criteria for this stage, and we believe it has the potential to address several hard-to-treat cancers through a clear biomarker-led strategy." said Dr Per Källblad, CEO of Beactica Therapeutics. "By moving this specific molecule into final candidate validation, we are executing on our mission to transition this program rapidly toward the clinic."

BEA-28 was selected after meeting predefined success criteria covering chemistry, in vitro and in vivo pharmacology, ADME and pharmacokinetic properties. The molecule will now advance into comprehensive candidate validation, including non-regulatory (pre-GLP) toxicology, scale-up chemistry, and advanced formulation profiling. Studies formally supporting IND-enabling requirements will be initiated following candidate drug nomination.

About BEA-28

BEA-28, closely related to P65-047, is a first-in-class, cereblon-recruiting small molecule degrader of the TEAD transcription factors, generated using Beactica’s Eclipsor platform and developed to shut down Hippo-YAP/TAZ-TEAD pathway activity implicated in tumour growth, immune evasion and resistance to targeted therapies. In preclinical studies, BEA-28 has shown deep responses in selected high-need lineages within a broad cancer cell line panel and reversed acquired resistance to KRAS-inhibitor treatment in cellular models. In vivo, BEA-28 achieved robust TEAD degradation in target tissue and induced tumour regression in xenograft models of mesothelioma and KRAS-mutant lung cancer at well-tolerated, once-daily doses. Beactica is developing BEA-28 alongside a biomarker-driven patient selection strategy intended to identify the tumours most likely to respond, with lead combination strategies planned in a non-mesothelioma high unmet need cancer alongside checkpoint inhibitors, and in KRAS-driven cancers alongside KRAS inhibitors. BEA-28 is investigational and has not been approved anywhere globally; its efficacy and safety in humans have not been established.

(Press release, Beactica, OCT 6, 2026, View Source [SID1234673238])

On October 6, 2026 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") reported that 21 abstracts from its oncology portfolio will be presented at the European Society for Medical Oncology Congress 2026 (ESMO 2026), taking place October 23–27 in Madrid, Spain. The presentations span prostate, urothelial, gastric/gastroesophageal junction (GEJ), lung and pancreatic cancers, reflecting Astellas’ commitment to advancing standards of care and pursuing new scientific approaches designed for cancers where significant unmet need remains.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Moitreyee Chatterjee-Kishore, Ph.D., MBA, Executive Vice President and Head of Oncology Development, Astellas:
"Standards of care do not change by accident. The data being presented at ESMO (Free ESMO Whitepaper) 2026 demonstrate how a deep understanding of disease biology and differentiated modalities is helping advance care for patients with bladder, gastric, and prostate cancers, including through approaches such as PADCEV (enfortumab vedotin) plus pembrolizumab, VYLOY (zolbetuximab), and XTANDI (enzalutamide). We are building upon this knowledge to develop the next generation of therapeutic options for cancers where unmet needs remain and look forward to engaging in discussions about this work at the congress."

Highlights from Astellas’ ESMO (Free ESMO Whitepaper) 2026 presentations include:

Enfortumab vedotin plus pembrolizumab presentations include the longest follow-up reported to date in locally advanced or metastatic urothelial cancer, along with analyses across patient subgroups and treatment settings. Additional presentations include trials in progress exploring bladder preservation in muscle-invasive bladder cancer.
Zolbetuximab presentations examine CLDN18.2 assessment, patient identification and real-world use, reinforcing the growing body of evidence supporting CLDN18.2-guided treatment decisions in gastric and GEJ cancers.
Pipeline presentations feature trials-in-progress across Astellas’ investigational programs, including Phase 3 trials of setidegrasib in KRAS G12D-mutated pancreatic and non-small cell lung cancers, a Phase 1 trial of ASP5834 in KRAS-mutated or amplified solid tumors, and a Phase 1b/2 trial of ASP546C in CLDN18.2-expressing solid tumors. Together, these investigational studies illustrate Astellas’ continued investment in advancing new approaches aimed at overcoming challenges that have limited progress in hard-to-treat cancers.
Additional details on Astellas’ presentations at ESMO (Free ESMO Whitepaper) 2026 are included below.

Presentation Title

Lead Author

Presentation Details

Enfortumab vedotin

EV-103 DE/Cohort A and Cohort K Final
Analysis: Enfortumab vedotin with or
without pembrolizumab as first-line
treatment for cisplatin (cis)-ineligible locally
advanced or metastatic urothelial
carcinoma: long-term follow-up analysis
from EV-103 cohorts DE/A and K

J. P. Maroto Rey

Type: Rapid oral
Abstract number: 4740RO
Date/time: Saturday, October 24,
10:15-11:45

EV-302 Comorbidities (DCO3):
Enfortumab vedotin plus pembrolizumab for
previously untreated locally advanced or
metastatic urothelial carcinoma: updated
exploratory analysis of EV-302 in older
patients and those with comorbidities

S. S. Sridhar

Type: Poster
Abstract number: 4761P
Date/time: Friday, October 23,
15:15-16:00

EV-302 Clinical Subgroups (DCO3):
Enfortumab vedotin + pembrolizumab in
previously untreated locally advanced or
metastatic urothelial cancer: exploratory
analyses based on disease-related
characteristics from EV-302

J. Bedke

Type: Poster
Abstract number: 4760P
Date/time: Friday, October 23,
15:15-16:00

EVOLVE 3: Real-world treatment patterns
in patients with locally advanced and
metastatic urothelial cancer in France

F. Joly

Type: ePoster

EV-303/KN-905 ITT3: Perioperative
pembrolizumab or enfortumab vedotin plus
pembro in participants with muscle-invasive
bladder cancer who are cisplatin-ineligible:
ad hoc analysis from KEYNOTE-905

A. Ullén

Type: Proffered paper session
Abstract number: 4733O
Date/time: Friday, October 23,
13:30-15:00

EV-304/KN-B15 ctDNA: ctDNA analysis of
the phase 3 KEYNOTE-B15 trial:
neoadjuvant and adjuvant enfortumab
vedotin + pembrolizumab for participants
with muscle-invasive bladder cancer who
are eligible for cisplatin

J. Chatzkel

Type: Proffered paper session
Abstract number: 4734O
Date/time: Friday, October 23,
13:30-15:00

EV-304/KN-B15 ePRO: Health-related
quality of life with neoadjuvant and adjuvant
enfortumab vedotin plus pembrolizumab in
participants (pts) with muscle-invasive
bladder cancer eligible for cisplatin in the
phase 3 KEYNOTE-B15 study

A. Gómez De Liaño

Type: Rapid oral
Abstract number: 4738RO
Date/time: Saturday, October 24,
10:15-11:45

EV-209 TiP: EV-209: an open-label, single-arm,
phase 2 study of enfortumab vedotin plus
pembrolizumab for bladder preservation in
patients with muscle-invasive bladder cancer
eligible for radical cystectomy

Thomas Powles

Type: Poster
Abstract number: 4769TiP
Date/time: Friday, October 23,
15:15-16:00

EV-309 TiP: EV-309: an open-label,
randomized, phase 3 study of enfortumab
vedotin plus pembrolizumab for bladder
preservation in patients with muscle-invasive
bladder cancer

Matthew D. Galsky

Type: Poster
Abstract number: 4770TiP
Date/time: Friday, October 23,
15:15-16:00

Enzalutamide

Adelpi REALIZE: High-risk biochemically
recurrent (hrBCR) hormone sensitive
prostate cancer (PC): European real-world
(RW) evidence on risk stratification, PSMA
PET use, and physician practices

A. Merseburger

Type: ePoster
Abstract number: 2063eP
Date/time: N/A

AMNOG NMA in mHSPC: Network meta-analysis
(NMA) on the safety of androgen receptor pathway
inhibitors (ARPIs) in patients with metastatic
hormone-sensitive prostate cancer (mHSPC) from
German AMNOG dossiers

C. Ohlmann

Type: Poster
Abstract number: 2295P
Date/time: Friday, October 23,
15:15-16:00

CASPER: Outcomes of enzalutamide
(ENZ) and apalutamide (APA) in metastatic
hormone-sensitive prostate cancer
(mHSPC): a Canadian real-world (RW) study

B. Shayegan

Type: ePoster
Abstract number: 2329eP
Date/time: N/A

ARCHES/ARANOTE indirect safety
comparison: Indirect safety comparison of
enzalutamide (ENZA) and darolutamide
(DARO) with androgen-deprivation therapy
(ADT) in metastatic hormone-sensitive
prostate cancer (mHSPC)

S. Shariat

Type: Poster
Abstract number: 2294P
Date/time: Friday, October 23,
15:15-16:00

EMBARK deep PSA response: Deep
prostate-specific antigen (PSA) response
by prior definitive treatment (tx) in patients
(pts) with high-risk biochemically recurrent
prostate cancer (hrBCR): EMBARK post
hoc analysis

S. Freedland

Type: Poster
Abstract number: 2293P
Date/time: Friday, October 23,
15:15-16:00

Zolbetuximab

SPOTLIGHT ctDNA: ctDNA Assessment in
Patients with CLDN18.2+, HER2−, Locally
Advanced Unresectable or Metastatic (la/m)
Gastric or Gastroesophageal Junction
Adenocarcinoma (G/GEJ a) in SPOTLIGHT

K. Shitara

Type: Poster
Abstract number: 2882P
Date/time: Sunday, October 25,
12:00-12:45

Canadian PSP: Real-World Use of
Zolbetuximab Plus Chemotherapy (CTx) in
Patients With CLDN18.2+, HER2−, Locally
Advanced (LA) Unresectable or Metastatic
Gastric or Gastroesophageal Junction
Cancer (mGC/GEJC) in a Canadian
Patient Support Program (PSP)

H. Karachiwala

Type: Poster
Abstract number: 2941P
Date/time: Sunday, October 25,
12:00-12:45

Pipeline

Phase 3 PDAC TiP: A Phase 3, double-blind,
randomized trial of setidegrasib + mFOLFIRINOX
or NALIRIFOX as first-line treatment for patients
with metastatic pancreatic ductal adenocarcinoma
(PDAC) harboring KRAS G12D mutations: Trial in
progress

T. Macarulla

Type: Poster
Abstract number: 3190TiP
Date/time: Sunday, October 25,
12:00-12:45

Phase 3 NSCLC TiP: Phase 3,
randomized, open-label trial of setidegrasib
vs docetaxel in patients with KRAS G12D-mutated
locally advanced or metastatic non-small cell lung
cancer (NSCLC) that progressed on or after
platinum-based chemotherapy and checkpoint inhibitor
(CPI) therapy: Trial in progress

F. Skoulidis

Type: ePoster
Abstract number: 2871eTiP
Date/time: N/A

Phase 1b/2 TiP: Phase 1b/2 study of
ASP546C, a Claudin 18.2-targeting
antibody-drug conjugate with a
topoisomerase 1 inhibitor payload, in
patients with Claudin 18.2-expressing
unresectable locally advanced or metastatic
solid tumors

T. Macarulla

Type: ePoster
Abstract number: 1133eTiP
Date/time: N/A

FiH TiP: A phase 1 study of ASP5834 in
patients with locally advanced or metastatic
solid tumors with Kirsten rat sarcoma viral
oncogene homologue (KRAS) mutations or
amplifications

S. Sen

Type: ePoster
Abstract number: 1145eTiP
Date/time: N/A

Combination clinical data for mss CRC:
A phase 1/2 study of ASP1570 for locally
advanced/metastatic microsatellite-stable
(MSS) colorectal cancer (CRC)

V. Boni

Type: ePoster
Abstract number: 1090eP
Date/time: N/A

(Press release, Astellas, OCT 6, 2026, View Source [SID1234673236])

On October 6, 2026 OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, reported its Investor & Analyst Day in Emeryville, CA. With a full presentation agenda, the event highlights recent partner developments, the broader roll out of the xPloration platform, and introduces the OmniTides peptide discovery platform and brand.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to bringing together our investment community and sharing a closer look at our technologies and capabilities, our strategy and the exciting opportunities ahead," said Matt Foehr, Chief Executive Officer of OmniAb. "At our Investor & Analyst Day, we have the opportunity to discuss our priorities and our plans related to our increasingly efficient business model, review the variety of ways we are creating value with technology licensing, and outline how we are positioning the company for sustainable, long-term growth. Those attending here at our Emeryville headquarters are also getting to experience demonstrations of our powerful xPloration platform, that we see as an additional pillar of significant value and growth for the business."

Featured Highlights at the Investor & Analyst Day:

OmniAb is highlighting its partner pipeline and partnerships as a key pillar of value for the business, with substantial contracted downstream potential milestones and royalties from a growing portfolio of later-stage programs that are described as best-in-class or first-in-class by its partners. Based on partner disclosures, OmniAb sees potential for primary completion of as many as 19 clinical trials evaluating OmniAb-derived drugs in the remaining months of 2026 and in 2027. OmniAb’s broad and growing base of partnerships provides a unique vantage point on the industry and informs the company’s strategic priorities as it leverages its highly differentiated suite of technologies.

xPloration Platform – Plans and Outlook

Beginning this month, the xPloration platform will be available for purchase by all customers, expanding commercial access beyond the Partner Access Program launched in 2025. Informed by positive partner feedback and primary market research, the broader launch of xPloration addresses a market opportunity of more than $500 million.

xPloration is an AI-powered, high-throughput single B-cell screening platform designed to streamline antibody discovery workflows by screening millions of antibody-secreting B cells and rapidly recovering thousands of antibody sequences, that:

Isolates B cells into approximately 1.5 million individual capillaries using proprietary chip technologies, with target cells loaded onto the array in less than 15 minutes;
Screens cells for desired antibody characteristics using automated imaging and AI/computer-vision analysis;
Can identify thousands of promising cells/positive hits in real time, with precision laser capability extracting selected live cells for immediate sequencing.
The expansion of commercial access for xPloration creates synergistic opportunities across OmniAb’s business lines, including technology licensing, and comes at a time when the industry is embracing the value of lab automation and big data generation for discovery.

The xPloration platform is positioned to deliver durable revenue streams to the business from instruments and related consumables. OmniAb expects xPloration revenue in 2026 to be between $2 million and $3 million and expects xPloration revenue to double in 2027 and to double again in 2028.

Introduction of OmniTides

OmniAb is introducing OmniTides, its peptide discovery offering powered by the OmniUltra transgenic chicken platform. The OmniTides platform is designed to provide an integrated discovery-to-synthesis workflow, with available peptide manufacturing by qualified CROs, to generate tailored, naturally optimized peptides for a range of therapeutic applications. By harnessing natural immune diversification, the platform offers a differentiated approach designed to identify functionally diverse OmniTide peptide candidates. The platform incorporates in vivo optimization driven by Biological Intelligence early in discovery and can support efficient progression to chemical synthesis and development.

The event is expected to begin with formal presentations at 11 a.m. ET / 8 a.m. PT. Participation is available for both in-person and virtual options, with a live webcast and presentation materials available on OmniAb investor relations page.

A replay of the webcast and presentation materials will be available following the event.

(Press release, OmniAb, OCT 6, 2026, View Source;Analyst-Day/default.aspx [SID1234673235])

On October 6, 2026 Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") reported that it has expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE with two additional exclusive targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to expand our collaboration with argenx, a recognized leader in immunology, building on the successful development of VYVGART Hytrulo," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "The addition of two new exclusive targets further validates the value and versatility of ENHANZE as the leading platform for rapid, large-volume subcutaneous delivery. As more companies seek to focus on patient convenience, reducing treatment burden and expanding access to important therapies, ENHANZE continues to be the technology of choice. This expanded agreement strengthens our growing portfolio of partnered programs and reinforces the significant long-term opportunity for ENHANZE across a broad range of therapeutic areas."

"Our partnership with Halozyme shows what co-creation can do for patients," said Arjen Lemmen, Vice President of Corporate Development and Strategy, argenx. "Together, we brought VYVGART Hytrulo to people living with MG and CIDP, which gave patients a subcutaneous option that fits more easily into their lives. Expanding to two more targets lets us bring that same focus on patient experience to more of our pipeline as we build a broader immunology portfolio. We’re proud to keep building on a partnership, rooted in shared ambition and scientific rigor."

Halozyme is eligible to receive payments upon achievement of agreed upon milestones and will receive royalties on net sales of products using ENHANZE.

(Press release, Halozyme, OCT 6, 2026, View Source [SID1234673234])

On October 6, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") reported that the first patients in the United States (U.S.) have been dosed with Pixclara (floretyrosine F 18 or 18F-FET), its FDA-approved, amino acid positron emission tomography (PET) drug for glioma (brain cancer) imaging.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The doses were administered at the Indiana University Health (IU Health) Neuroscience Center in Indianapolis and the University Hospitals, Cleveland Medical Center, Cleveland. The milestone marks the start of commercial availability for Pixclara, with Telix’s U.S. manufacturing and pharmacy distribution partner, PharmaLogic Holdings Corp. (PharmaLogic), supplying finished unit doses to the U.S. market.

Pixclara is a radioactive diagnostic drug indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients one month of age and older.

Na Tosha N. Gatson, MD, PhD, FAAN, director of the Center for Neuro-Oncology as part of the Neuroscience & Cancer Institutes with IU Health-Indiana University School of Medicine; tenured professor, Neurology, Neurosurgery, & Medicine, IUSM, and Founding President of the nonprofit, Living Oncology said, "Distinguishing recurrent or progressive gliomas from treatment-related change is one of the most difficult and consequential challenges in brain cancer. Having access to FDA-approved FET-PET1 imaging with Pixclara will help clinicians make more timely and accurate decisions, minimizing uncertainty in their diagnoses and supporting more confident treatment planning for patients with gliomas."

Clement Pillainayagam, MD, Specialist in Neurology and Neuro-oncology, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, added, "The approval and commercial availability of Pixclara represents an advance for patients with glioma in the U.S. FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines2, and having an FDA-approved, commercially available option can help translate this established clinical approach into broader access for patients, adding another tool to help in their care."

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, continued, "The first commercial dose of Pixclara is an important milestone for a patient community that has seen limited advances in diagnosis and treatment for many years. We are proud to support patients with glioma and their care teams by bringing this important new precision diagnostic to the U.S., and we thank the clinicians, patients, advocates and broader neuro-oncology community who helped make this possible."

About gliomas

Gliomas are the most common form of central nervous system (CNS) cancer, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors3. In the U.S., approximately 24,000 new glioma cases are diagnosed each year4, representing a significant unmet addressable need.

About Pixclara (floretyrosine F 18)

Pixclara is an intravenous positron emission tomography (PET) imaging drug for the differentiation of recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older. It comprises a small molecule targeting compound labeled with a diagnostic radioisotope, fluorine-18. After administration into the bloodstream, Pixclara targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). Once bound, energy emissions from the radioisotope can be detected by a PET scanner. Pixclara (TLX101-Px) is also the subject of a Phase 3 registrational study for potential indication expansion for the diagnosis of brain metastases5.

Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer).

INDICATIONS AND USAGE
PIXCLARA is indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
Risk for Misinterpretation

Image misinterpretation may occur with PIXCLARA PET. A negative image does not rule out the presence of recurrent or progressive glioma and a positive image does not confirm the presence of recurrent or progressive glioma. Equivocal findings may occur with PIXCLARA PET, including low-level or atypical uptake patterns, which may result in false positive or false negative interpretations.

Interpret PIXCLARA PET findings with caution and correlate results with available clinical evaluations, such as histopathology, cross-sectional imaging, and/or clinical history to support appropriate clinical decision-making.

Radiation Risks

PIXCLARA contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe drug handling to protect patients and health care providers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.

ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PIXCLARA was evaluated in 382 patients with gliomas. Among these 382 patients, 371 adult patients received at least one intravenous dose of PIXCLARA at a mean activity of 204 ± 18 MBq (5.5 ± 0.47 mCi). The remaining 11 pediatric patients received at least one intravenous dose of PIXCLARA at a mean activity of 155 ± 53.5 MBq (4.2 ± 1.4 mCi).

The mean age of the patients was 57 years (range: 5 years to 86 years). Sex was 59% male, 37% female, and 3% unreported. Distribution by race was 26% White, 6% Asian, <1% Black or African American, and 67% other or unreported. Distribution by ethnicity was 3% Hispanic/Latino, 96% non-Hispanic/Latino, and <1% unknown or unreported.

Adverse reactions that occurred in ≥0.5% of patients receiving PIXCLARA were headache (0.5%).

Adverse reactions that occurred in <0.5% of patients were nausea, injection site reaction, fatigue, and malaise.

Adverse Reactions in Pediatric Patients

Overall, the safety profile observed in pediatric patients from the clinical study was consistent with the safety profile in adult patients.

(Press release, Telix Pharmaceuticals, OCT 6, 2026, View Source [SID1234673233])